Beer Kenneth, Glogau Richard G, Dover Jeffrey S, Shamban Ava, Handiwala Lata, Olin Jason T, Bulley Brian
*Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania; †Department of Dermatology, University of California, San Francisco, California; ‡Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut; §Department of Dermatology, Geffen School of Medicine, University of California Los Angeles, Los Angeles, California; ‖Valeant Aesthetics, a Division of Valeant Pharmaceuticals North America LLC, Bridgewater, New Jersey; ¶Inergy Limited, Lindfield, United Kingdom.
Dermatol Surg. 2015 Apr;41 Suppl 1:S127-36. doi: 10.1097/DSS.0000000000000199.
To compare the safety and effectiveness of small particle hyaluronic acid plus lidocaine (SPHAL) versus no treatment for lip augmentation and perioral rhytides.
Adults scoring 1 (very thin) to 2 (thin) on the Medicis Lip Fullness Scale (MLFS) for upper and lower lips were randomized (3:1) to SPHAL or no treatment. Treatment success was an MLFS increase ≥1 point at Week 8. Secondary end points (MLFS score, independent photographic review, Global Aesthetic Improvement Scale, Wrinkle Assessment Scale for Upper Lip Lines) and safety were assessed throughout.
Statistically significantly more patients were treatment successes with SPHAL (upper lip [80.2% vs 11.9%], lower lip [84.2% vs 18.4%], and upper and lower lips combined [76.1% vs 11.6%]), compared with no treatment (p <.001, all outcomes). Patients treated for both lip augmentation and perioral rhytides were rated as having an aesthetically meaningful improvement in perioral rhytides (p <.001). Most common treatment-emergent adverse events (AEs) included lip bruising, swelling, and pain and were mostly mild and transient in nature, without anticipated device AEs.
Small particle hyaluronic acid plus lidocaine was effective and well tolerated and significantly more effective when both lips and perioral rhytides were treated, with improvement evident up to 6 months after treatment.
比较小颗粒透明质酸联合利多卡因(SPHAL)与不治疗用于丰唇及改善口周皱纹的安全性和有效性。
根据Medicis唇部丰满度量表(MLFS),上唇和下唇评分为1(非常薄)至2(薄)的成年人被随机分组(3:1),分别接受SPHAL治疗或不治疗。治疗成功的定义为在第8周时MLFS增加≥1分。在整个过程中评估次要终点(MLFS评分、独立照片评估、整体美学改善量表、上唇皱纹评估量表)和安全性。
与不治疗相比,接受SPHAL治疗的患者治疗成功的比例在统计学上显著更高(上唇[80.2%对11.9%],下唇[84.2%对18.4%],上下唇联合[76.1%对11.6%])(所有结果p<.001)。接受丰唇和口周皱纹治疗的患者在口周皱纹方面被评为有美学意义的改善(p<.001)。最常见的治疗中出现的不良事件(AE)包括唇部瘀伤、肿胀和疼痛,大多性质轻微且短暂,未出现预期的器械相关不良事件。
小颗粒透明质酸联合利多卡因有效且耐受性良好,在同时治疗唇部和口周皱纹时效果显著更优,治疗后6个月仍有明显改善。